Details for Patent: 9,457,093
✉ Email this page to a colleague
Which drugs does patent 9,457,093 protect, and when does it expire?
Patent 9,457,093 protects TUKYSA and is included in one NDA.
This patent has forty-nine patent family members in thirty-two countries.
Summary for Patent: 9,457,093
| Title: | Solid dispersions of a ERB2 (HER2) inhibitor |
| Abstract: | A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dim- ethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-.alpha.]pyridin-7-yloxy)-3-methylphenyl)-N6-(4- ,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein. ##STR00001## |
| Inventor(s): | Fry; David Shank (Boulder, CO), Lindemann; Christopher M. (Boulder, CO), Preigh; Michael (Boulder, CO), Bloom; Corey Jay (Boulder, CO), Craig; Christopher Donovan (Boulder, CO), Dubose; Devon Brevard (Boulder, CO), Gautschi; Jeff (Boulder, CO), Smithey; Dan (Boulder, CO) |
| Assignee: | Array BioPharma Inc. (Boulder, CO) |
| Application Number: | 14/351,840 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Process; Dosage form; |
Drugs Protected by US Patent 9,457,093
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-001 | Apr 17, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER | ⤷ Sign Up | |||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-002 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,457,093
| PCT Information | |||
| PCT Filed | October 12, 2012 | PCT Application Number: | PCT/US2012/060044 |
| PCT Publication Date: | April 18, 2013 | PCT Publication Number: | WO2013/056108 |
International Family Members for US Patent 9,457,093
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2765990 | ⤷ Sign Up | 2021029 | Norway | ⤷ Sign Up |
| Australia | 2012322039 | ⤷ Sign Up | |||
| Australia | 2017210499 | ⤷ Sign Up | |||
| Australia | 2019200243 | ⤷ Sign Up | |||
| Brazil | 112014009092 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
